Bought some of these this morning as Instiutional interest as really boiled up over them. They have just announced a very positive deal and from what I can see theres quite a lot of news flow in the pipeline to keep this one going throughout the rest of the year. Its highly speculative but give me a Bio company that isnt.

Heres just a little historical detail about the company from the last results prelims 31/12/2004.

HIGHLIGHTS

Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004

POST YEAR-END EVENTS

Patent for Trinam(R) granted by European Patent Office

Dr Nigel Parker, CEO of Ark, commented:

'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'

ARKs History

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.

Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.

Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.

You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html

Worth a punt I feel but as I have previously stated its high risk.

DYOR.

cheers GF.

Looks ready to tick up.

cheers GF.

Thanks GF, i`m in on this one and feel very confident about it finishing blue today. All the best.....

Wellcome aboard Dandu71. Looking for a lot more capital appreciation here.

cheers GF.

All buys this morning so far.

cheers Gf.

Nice to see these moving upwards.

cheers Gf.

Play of the Week in Shares mag this morning and an RNS

Yup a BUY in shares mag and this from CityWire..................

Good news on CityWire today.............

More good news keeps Ark buoyant

Published: 14:27 Thursday 14 April 2005
Citywire tip and BrainsTrust constituent Ark Therapeutics has maintained its recent flow of good news with further positive news from a trial of a drug to help reduce side effects for HIV patients on anti-retroviral drugs.

Ark's shares (AKT) are 1.5p higher at 127p, a new high for the year, after completing an exploratory phase II study of its EG005 treatment for lipodystrophy.

Lipodystrophy is characterised by the potentially harmful build up of body fat in the central area of the body in patients on anti-retroviral treatments. This build up of a 'pot belly' increases the risk of cardiovascular disease. Ark's treatment has shown to be effective in reducing the condition during a three month study and the majority of patients have now signed up for another year of the study.

Ark now anticipates it may be able to commence a phase III study next year.

This adds to Ark's portfolio of potential products, it already has the Kerraboot leg and foot ulcer treatment product on sale and treatments for brain tumours and muscle wasting in various stages of development. Less than a month ago it also signed an agreement with German pharmaceutical giant Boehringer giving it intellectual property rights to therapies for cardiovascular ailments.

Citywire tipped Ark at 119p last week after revealing top fund managers AAA-rated Roger Whiteoak of Framlington and New Star's Jamie Allsopp had recently increased their exposure to the company. Analysts from Nomura, Numis and Credit Suisse First Boston have also recently issued buy recommendations with price targets ranging from 145p to 163p.

The share price has risen a little and is likely to continue to tick ahead as good news continues to come through during the year ahead.

Ark holds a place in the top 30 of Citywire's BrainsTrust Small Cap index of stocks most favoured by the best performing UK Smaller Companies fund managers.

cheers GF.

Featured last week in IC, hoping theres a further back up article.

cheers Gf.

A good time to buy these, profit taking going on here.

cheers GF.

Agreed GF, not at all taken back by the red this morning, profit taking and market sentiment I feel. D

Dandu71, certainly presents them not in with the chance of buying cheap.

cheers GF.

Good to see this ticking up gradually the last couple of days.

Some good news:

Ark Therapeutics says new technology prevents gene being inserted in wrong place
AFX


LONDON (AFX) - Ark Therapeutics Group PLC said its scientists have discovered a new delivery technology for gene therapy which avoids a gene being inserted in the wrong place, preventing potentially harmful consequences.

The company said current delivery technology used in clinical trials is not site-specific and therefore carries the risk of a gene insertion into an undesired and potentially harmful position on the chromosomes.

Ark said these risks became apparent in a trial in 2002, where some patients treated for immune deficiency disease developed a leukaemia-like disease as a result of undesired gene insertion.

The company said its novel technology 'could herald a breakthrough in molecular medicine because it removes the potentially harmful consequences of a beneficial therapeutic gene being inserted into the wrong place, and could thus greatly improve the predictability and safety of gene therapy'.

newsdesk@afxnews.com

Anyone with views on those large WT trades today?

Looks to me like at least some are probably serious buys, made over the last 24 hours. Good news if true, but it ain't necessarily so...

Cheers, Madison

Massive volume on these recently. I hope it's still in the top 30 favoured by best performing small companies fund managers and it's their buying...

Cheers, Madison

Well I've just bought in. I have a very good feeling about Ark and it's product pipeline so hoping to enjoy the ride!

Ark Therapeutics Group PLC
05 October 2005

Ark completes development of oxLDL diagnostic kit for prediction of heart attack
risk

Product now CE-marked in preparation for commercialisation


London, UK, 5 October 2005: Ark Therapeutics Group plc ('Ark'), today announces
that it has completed the development and European CE marking of its oxidised
low density lipoprotein antibody testing kit, oxLDL. The diagnostic kit will be
used to predict whether an individual is at risk of having a heart attack.

Patients with cardiovascular disease exhibit a build up of fats and abnormal
tissue, known as atherosclerotic plaques, on the inside of their blood vessels.
Whilst plaques can lay dormant with minimal risk to the patient, they can become
active and unstable, eventually rupturing and releasing fragments of plaque into
the bloodstream. This 'breakaway' plaque is circulated by the blood and can
lodge in the coronary artery causing a heart attack, or in the blood vessels
supplying the brain causing a stroke.

As plaque becomes active, it releases a specific chemical, an oxidised form of
low density lipoprotein (oxLDL), into the blood stream in amounts that reflect
the level of the plaque's instability. As such, oxLDL has become increasingly
recognised as a key marker of heart attack risk(1), as the higher its level in
the blood, the more likelihood there is of the plaque breaking away and causing
a serious cardiovascular event.

Attempts to produce a reliable and easy to use test to measure oxLDL have not
been successful to date, as the oxLDL molecule only exists for a very short time
in the blood. However, as oxLDL is released into the blood, it rapidly produces
an antibody response. Ark's test, the first of its kind, is a highly sensitive
measure of the level of antibodies that are produced in response to oxLDL. The
test also contains a control chemical to check whether a positive result is real
or false.

Clinical results to date using Ark's test have shown that the test is applicable
to approximately 75% of people and is highly predictive. In a study of patients
with chest pain entering hospital for investigation, 81% of the patients who
tested positive using Ark's kit were subsequently confirmed as having a serious
cardiovascular problem (heart attack or unstable angina). The test was even
more accurate where heart attack occurred. C-reactive protein (CRP), one of the
current 'gold standards' in predicting risk of cardiovascular problems, was
predictive in only 29% of the cases in the same study.

Professor John Martin, Chair of Cardiovascular Medicine at University College
London and Chief Scientific Officer at Ark, commented: 'This new diagnostic is
highly predictive and has the potential to save many lives. It should prove a
very useful addition to the overall cardiovascular risk testing approach.'

Dr Nigel Parker, Chief Executive of Ark, added: 'This is the second product that
Ark has taken all the way through the development process to CE marking. We
shall now be seeking specialist diagnostic partners to help us market the
product and ensure that it realises its full commercial potential.'

Cheers, Madison

Excellent news, thanks Madison!

And more again:

Ark Therapeutics Group PLC
20 October 2005


Ark receives licence to manufacture first gene medicine for commercial supply


London, UK, 20 October 2005: Ark Therapeutics Group plc ('Ark') announces today
that, following an inspection by the Finnish National Agency for Medicines, on
behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland
has received Good Manufacturing Practice (GMP) Certification to manufacture
commercial supplies of its adenoviral-based gene medicine CereproTM, a gene
based medicine for the treatment of brain cancer.

Ark's facility, in Kuopio, Finland is believed to be the only facility outside
of China to have been licensed to manufacture gene based medicines for
commercial supply.

Nigel Parker, CEO of Ark, commented: 'This is a tremendous achievement by the
Company. A number of years of meticulous planning and work have gone into
achieving this certification and it endorses our leadership position in this
upcoming area of molecular medicine.'

Cheers, Madison

Again, great news Madison. Is momentum building now for a push higher?